David Planchard

News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me

David Planchard
Mar 30, 2025, 04:59 | Blog
Mohamed Emam Sobeih: Excited to share my poster at ELCC 2025
Mohamed Emam Sobeih, Deputy Director and Medical Oncology Consultant at the National Cancer Institute, shared…
Mar 27, 2025, 10:48 | Blog
David Planchard: Post-Osimertinib Strategies in EGFRmut NSCLC - Savannah and Orchard Studies
David Planchard, Thoracic Pathologist Committee at Gustave Roussy, shared a post on X: "Two superb post osimertinib…
Mar 26, 2025, 14:18 | Blog
David Planchard: Take home messages by Fabrice Barlesi on oncogenic treatment of localised NSCLC in 2025
David Planchard, Thoracic Pathologist Committee at Gustave Roussy, shared a post on X: "Clear messages…
Mar 24, 2025, 09:05 | Blog
David Planchard: Neoadjuvant and adjuvant treatments for lung cancer to optimize patients' survival
David Planchard, Thoracic Oncologist and Professor at the University Paris Saclay, posted on LinkedIn: "So…
Mar 18, 2025, 12:17 | Blog
Raffaele Califano: Another great ESMO preceptorship in lung cancer
Raffaele Califano, Professor of Medical Oncology at The University of Manchester, posted on LinkedIn: "Last…
Mar 14, 2025, 13:20 | Science
David Planchard: Unparalleled benefit of Osimertinib for EGFR-mutated advanced NSCLC
David Planchard, Thoracic Oncologist and Professor at the University Paris Saclay, shared an article by…
Feb 1, 2025, 17:20 | Blog
David Planchard: Scientific exchange on lung cancer and conviviality at Gustave Roussy
David Planchard, Thoracic Oncologist, Professor at the University Paris Saclay, Head of the Thoracic Group…
Jan 27, 2025, 09:44 | Blog
David Planchard: Resistance to targeted therapies in the lung from a clinical and translational research angle
David Planchard, Thoracic Oncologist, Professor at the University Paris Saclay, Head of the Thoracic Group…
Jan 8, 2025, 14:07 | Science
Rami Manochakian: Results of TROPION/Lung05 Phase 2 trial are out
Rami Manochakian shared a post on X: "Hot off the press. Just published in the Journal…
Dec 26, 2024, 14:13 | Blog
David Planchard: Welcoming Mohyeldin Abdelhalim to attend thoracic consultations at the Gustave Roussy Institute
David Planchard, Head of Thoracic Oncology Group at Gustave Roussy, shared on LinkedIn: “It was…
Dec 2, 2024, 09:46 | Positive
Top 100 Xfluencers in Lung Cancer: Key Opinion Leaders to Follow on X (Twitter) in 2024
As November came to a close, it's an ideal time to reflect on Lung Cancer…
Nov 20, 2024, 16:38 | Insight
Herbert Loong: NTRK gene fusion testing in the management of NSCLC
Herbert Loong, Chair-Elect of the International Affairs Committee of ASCO, shared a post on X…
Nov 18, 2024, 16:31 | Insight
Andreas Koulouris: Incredible opportunity to participate in the Lung Cancer Preceptorship in Paris
Andreas Koulouris, Consultant in Oncology at Karolinska University Hospital, shared a post on X: “Grateful…
Nov 17, 2024, 23:54 | Opinion
David Planchard: Happy to see our young Gustave Roussy - lung oncologists
David Planchard, Head of Thoracic Oncology Group at Gustave Roussy, shared on LinkedIn: "Happy to…
Oct 2, 2024, 14:41 | Insight
Stephen Liu: Phase Ib study of naporafenib with rineterkib or trametinib in NSCLC
Stephen Liu shared a post on X about a recent paper by David Planchard et…
Sep 22, 2024, 14:45 | Blog
Amol Akhade: ADC In NSCLC
Amol Akhade shared a post on LinkedIn: "ADC In NSCLC. All Drugs in One Slide .…
Sep 19, 2024, 04:32 | Societies
Best of ESMO24
The ESMO Congress 2024 took place in Barcelona, from September 13 to 17, 2024, at…
Sep 15, 2024, 16:26 | Societies
43 Posts Not To Miss From ESMO24 Day 2
The ESMO Congress 2024 is ongoing in Barcelona, from September 13 to 17, 2024, at the…
Sep 11, 2024, 06:39 | Blog
Stephen Liu: Looking forward to discussing updates in ADCs for lung cancer at WCLC24
Stephen Liu shared a post on X: “Looking forward to WCLC24 - join us for lunch…
Sep 7, 2024, 07:32 | Insight
5 papers about lung cancer suggested by Stephen Liu
Stephen Liu, Head of Developmental Therapeutics at Georgetown Lombardi Comprehensive Cancer Center, shared a few…
Aug 27, 2024, 22:06 | Insight
Giuseppe Banna: Promising results for Telisotuzumab Vedotin in advanced NSCLC
Giuseppe Banna, Consultant Medical Oncologist at Portsmouth Hospitals University NHS Trust, shared a post on…
Jul 18, 2024, 10:05 | Insight
EMA Joins FDA: Osimerintib + Chemo Approved for EGFR-Mutated Lung Cancer
Breaking News: EMA Joins FDA in Approving Osimerintib with Chemotherapy as a New 1st-Line Treatment…
Jul 13, 2024, 11:17 | Blog
David Planchard: New option in the 1st line strategy for NSCLC EGFRmut patients
David Planchard, Thoracic Oncologist at Gustave Roussy, shared on LinkedIn: "Great news, a new option…
Jun 27, 2024, 14:15 | Blog
David Planchard: Nice post-ASCO24 at Gustave Roussy with the lung session
David Planchard shared on LinkedIn: "Nice post-ASCO24 Gustave Roussy with the lung session. What wonderful…
May 19, 2024, 06:05 | Insight
Herbert Loong: Our latest recommendations for NTRK fusion testing and management in lung cancer
Herbert Loong shared on X: "We have recently published our latest recommendations for NTRK fusion…
May 10, 2024, 14:48 | Blog
Rémi Thiolet: Gustave Roussy had the honor to meet the PM of Egypt and Minister of Health and Population
Rémi Thiolet, International advisor and Head of International Affairs at Gustave Roussy, shared on LinkedIn:…
May 9, 2024, 06:46 | Societies
12 Posts Not To Miss From The 3rd International Summit on Lung Cancer!
The 3rd International Summit on Lung Cancer (RomeLung24), organized by the International Association for the…
May 1, 2024, 10:06 | Insight
David Planchard: Proud to present 1st results of ICARUS-Lung 01 study
David Planchard, Professor at the University of Paris-Saclay, posted on LinkedIn: “Superb oral session on…
Apr 23, 2024, 23:52 | Blog
David Planchard: The new Medical Oncology department opened at the Gustave Roussy
David Planchard, Professor at the University of Paris-Saclay, posted on LinkedIn: “While we await the opening…
Apr 20, 2024, 06:18 | Insight
New Paper Alert! Addressing BRAF V600E in Metastatic Non-Small Cell Lung Cancer
Addressing BRAF V600E in Metastatic Non-Small Cell Lung Cancer Authors: David Planchard, Rachel E. Sanborn,…
Apr 20, 2024, 06:08 | Insight
David Planchard: Some advances for our BRAF V600E NSCLC patients…Review to read at npj Journals
David Planchard, Professor at the University of Paris-Saclay, posted on X/Twitter: "Some advances for our BRAF…
Apr 13, 2024, 09:17 | Societies
30 Posts Not To Miss From AACR24!
The AACR Annual Meeting 2024 was held from April 5th to 10th in San Diego,…
Feb 27, 2024, 19:03 | Blog
Humaid Al-Shamsi: We had the pleasure to share our experience with Prof. Planchard in treating 10 complex lung cancer cases
Humaid Al-Shamsi, Director of Burjeel Cancer Institute (BCI), posted on LinkedIn: "With Prof. David Planchard…
Dec 12, 2023, 12:40 | Societies
20 Posts Not To Miss From ESMO Asia Congress 2023
The ESMO Asia Congress 2023 took place in Singapore from 1 to 3 December. Our…
Nov 12, 2023, 17:56 | Drugs
David Planchard: Thank you to the patients who actively participated in this research
David Planchard, Professor at the University Paris Saclay, posted on X/Twitter. "Proud to lead this…
Aug 22, 2023, 09:53 | Blog
David Planchard: Amphitheater full, impressive and top organization by the ESMO staff.
Quoting David Planchard, Thoracic Oncologist and Head of Thoracic Cancer Group at Gustave Roussy, stated…
All: 36 Posts: 1 - 100
Special Coverage